\n
\r\n
<\/a>\r\n<\/div><\/p>\n<\/div><\/section><\/div>

\r\n\r\n
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\nSynexa Life Sciences expands biomarker discovery capabilities with the addition of Olink Target Platform<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>

\n
Synexa Life Sciences expands biomarker discovery capabilities with the addition of Olink Target Platform<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nSynexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, has integrated the Olink Target immunoassays and the Olink Signature Q100 instrument into its extensive suite of biomarker discovery platforms.<\/h3>\n<\/p>\n
The adoption of Olink Signature Q100 represents a significant step forward in Synexa’s commitment to providing leading biomarker and bioanalytical solutions to its pharma and biotech customers. Olink Signature Q100 processes and analyses Olink Target assays in the format of disease-focused panels that require as little as 1 \u03bcL of serum, plasma, or other biological sample types. Profiled protein biomarkers reveal deeper insights into disease mechanisms, identifying potential therapeutic targets, and accelerating the development of innovative treatments.<\/p>\n<\/div><\/section>
\n
Synexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, has integrated the Olink Target immunoassays and the Olink Signature Q100 instrument into its extensive suite of biomarker discovery platforms.<\/h3>\n<\/p>\n
The adoption of Olink Signature Q100 represents a significant step forward in Synexa’s commitment to providing leading biomarker and bioanalytical solutions to its pharma and biotech customers. Olink Signature Q100 processes and analyses Olink Target assays in the format of disease-focused panels that require as little as 1 \u03bcL of serum, plasma, or other biological sample types. Profiled protein biomarkers reveal deeper insights into disease mechanisms, identifying potential therapeutic targets, and accelerating the development of innovative treatments.<\/p>\n<\/div><\/section>
\n
\n